clinical trial · NCT06807632
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Extensive-stage Small-cell Lung CancerValemetostatAtezolizumab
brief summary
This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC). The researchers will test different doses of valemetostat to find the highest dose that causes few or mild side effects in participants. After the dose is found, researchers will test it in a new group of participants to learn more about the safety of the study treatment and see if it is an effective treatment for extensive-stage SCLC.
started
Jan 29, 2025
primary completion
Jan 1, 2027
completion
Jan 1, 2027
last updated
Jun 8, 2026
official title
Phase I Study of Valemetostat and Atezolizumab as Maintenance Therapy for Patients With Extensive-Stage Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol